Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia

Table 2 Sustained virologic response by previous treatment, interleukin-28B genotype, and on-treatment virologic response n (%)

	Boceprevir plus PR (n = 159)	PR (n = 78)
Treatment naive	76/97 (78.4)	27/48 (56.3)
Treatment experienced	43/62 (69.4)	9/30 (30.0)
Null responder	8/17 (47.1)	1/6 (16.7)
Partial responder	5/8 (62.5)	1/4 (25.0)
Relapser	30/37 (81.1)	7/20 (35.0)
Treatment naive
IL28B CC genotype	19/20 (95.0)	11/11 (100.0)
IL28B non-CC genotype	57/77 (74.0)	16/37 (43.2)
Treatment experienced
IL28B CC genotype	2/2 (100.0)	0/0
IL28B non-CC genotype	41/60 (68.3)	9/30 (30.0)
SVR according to baseline HCV RNA
All patients
≤ 800000 IU/mL	71/89 (79.8)	25/53 (47.2)
> 800000 IU/mL	48/70 (68.8)	11/25 (44.0)
Treatment naive
≤ 800000 IU/mL	45/52 (86.5)	16/27 (59.3)
> 800000 IU/mL	31/45 (68.9)	11/21 (52.4)
Treatment experienced
≤ 800000 IU/mL	26/37 (70.3)	9/26 (34.6)
> 800000 IU/mL	17/25 (68.0)	0/4 (0)
SVR according to TW4 response
TW4 < 1 log drop	20/43 (46.5)	0/22 (0)
TW4 ≥ 1 log drop	75/90 (83.3)	26/45 (57.8)
TW4 undetectable	23/23 (100)	10/10 (100)
Missing	1/3	0/1
SVR according to TW8 response
TW8 undetectable	115/139 (82.7)	29/33 (87.9)
TW8 detectable	4/16 (25)	7/44 (15.9)
Missing	0/4	0/1
SVR according to presence of anemia
Yes	47/66 (71.2)	6/11 (54.5)
No	72/93 (77.4)	30/67 (44.8)
SVR according to EPO use
Yes	10/15 (66.7)	3/3 (100)
No	109/144 (75.7)	33/75 (44)
SVR according to ribavirin dose reduction
Yes	46/67 (68.7)	12/17 (70.6)
No	73/92 (79.4)	24/61 (39.3)

SVR is defined as the virologic response at follow-up week 24. If a patient had missing data at and after the follow-up week 24 window and had undetectable HCV RNA at follow-up week 12, the patient was considered a sustained virologic responder. EPO: Erythropoietin; HCV: Hepatitis C virus; SVR: Sustained virologic response; TW: Treatment week; PR: Peginterferon/ribavirin; IL28B: Interleukin-28B.